Total
0
Shares
Genetic Technology’s (ASX:GTG) break-through breast cancer technology to go on sale in 2020
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Genetic Technologies (GTG) has entered into a conditional agreement to procure US$6.6 million (around A$8.58 million) via an institutional share placement
  • All up, 1.25 million American Depositary Shares (ADS's), representing 600 of the company's ordinary shares, are set to be issued as part of the placement
  • According to GTG, the proceeds will go towards advancing the company's operations in the U.S. and Europe as well as product research and development
  • GTG shares have rocketed up 33.3 per cent on the back on the announcement, trading at 1.2 cents each

Genetic Technologies (GTG) has entered into a conditional agreement to procure US$6.6 million (around A$8.58 million) via an institutional share placement.

Several undisclosed institutional investors have entered into the agreement for the purchase and sale in a registered direct offering of 1.25 million American Depositary Shares (ADS's).

Each ADS represents 600 of the company’s ordinary shares, at a
purchase price of US$5.25 (A$0.01125) per share, to raise US$6.56 million (roughly A$8.58 million.

According to GTG, the proceeds from the raise are set to be used in the introduction and distribution of its new products in the United States and
Europe, product research and development, and preparation for its COVID-19 severity risk test.

The securities described above are being offered by the company pursuant to a "shelf" registration statement previously filed with the U.S. Securities and Exchange Commission, which was granted on March 23, 2020.

The offering is expected to close on or about January 25, subject to the satisfaction of conditions.

GTG shares have rocketed up 33.3 per cent on the back on the announcement, trading at 1.2 cents each market close.

GTG by the numbers
More From The Market Herald
Patrys (ASX:PAB) selects stable cell line for PAT-DX1 production

" AFT Pharmaceuticals (ASX:AFP) signs exclusive Maxigesic IV licensing agreement

AFT Pharmaceuticals has signed an exclusive Maxigesic IV licensing agreement for eight new European markets.
Althea Group (ASX:AGH) - CEO, Joshua Fegan - The Market Herald

" Althea Group’s (ASX:AGH) subsidiary gets A$137K order to make cannabis concentrates

Althea Group’s (AGH) subsidiary, Peak Processing Solutions, has received an C$134,000 (roughly A$137,216) purchase order from Peace Naturals Project.
Immutep (ASX:IMM) - CEO, Marc Voigt (left) - The Market Herald

" Immutep (ASX:IMM) expands TACTI-002 study

Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a recommendation from the data monitoring committee.
ImpediMed (ASX:IPD) - CEO, Rick Carreon - The Market Herald

" ImpediMed (ASX:IPD) completes 200,000 patient tests

ImpediMed  (IPD) says it has reached a milestone 200,000 patient tests for SOZO testing.